The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?

Antonio Galvano, Francesco Passiglia, Giuseppe Bronte, Daniele Fanale, Antonio Russo, Angela Listi', Lorena Incorvaia, Viviana Bazan, Christian Rolfo, Clara Natoli, Christian Diego Rolfo, Fabio Rizzo, Sergio Rizzo

Risultato della ricerca: Article

11 Citazioni (Scopus)

Abstract

Malignant pleural mesothelioma (MPM) is an aggressive tumor of the pleura with a poor prognosis. The most active first-line regimens are platinum compounds and pemetrexed. There is no standard second-line treatment in MPM. Advances in the understanding of tumor molecular biology have led to the development of several targeted treatments, which have been evaluated in clinical trials. Unfortunately none of the explored targeted treatments can currently be recommended as routine treatment in MPM. We reviewed the biological pathways involved in MPM, the clinical trials about targeted therapy, and possible related mechanisms of resistance. We suggest that specific genetic markers are needed as targets of selective therapy. By this way the selection of patients based on the molecular profile may facilitate a therapeutic strategy that allows the use of the most appropriate drug for each patient.
Lingua originaleEnglish
pagine (da-a)20-32
Numero di pagine13
RivistaCRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
Volume107
Stato di pubblicazionePublished - 2016

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Fingerprint Entra nei temi di ricerca di 'The resistance related to targeted therapy in malignant pleural mesothelioma: Why has not the target been hit yet?'. Insieme formano una fingerprint unica.

  • Cita questo